

Claims:

1. The use of substances of the porphyrin synthesis or pharmacologically compatible salts thereof for the production of pharmaceuticals for application of phototherapy with light having a wavelength of 400 to 700 nm, as well as for the treatment of psoriasis and of inflammatory processes of the skin and/or joints of mammals and humans.
2. The use according to claim 1, characterized in that a salicylate is additionally used as the active ingredient.
3. The use according to claim 2, characterized in that an antioxidant is additionally used as the active ingredient.
4. The use according to claims 1 to 3, characterized in that 5-aminolevulinic acid (ALA) is used as the substance of the porphyrin synthesis.
5. The use according to claims 1 to 4, characterized in that acetylsalicylic acid is used as the salicylate.
6. The use according to claims 1 to 5, characterized in that ascorbic acid or a pharmacologically compatible salt thereof is used as the antioxidant.
7. The use according to claims 1 to 6, characterized in that the wavelength of the light is 400 to 700 nm.
8. The use according to claim 7, characterized in that the wavelength of the light is approximately 545 nm.

9. The use according to claims 1 to 8 for the treatment of arthritis, plaque psoriasis, arthritic psoriasis, neuropathies such as carpal tunnel syndrome or Bekhterev's disease.

10. The use of substances of the porphyrin synthesis according to claims 1 to 9 for phototherapy.